Please login to the form below

Not currently logged in
Email:
Password:

QuintilesIMS

This page shows the latest QuintilesIMS news and features for those working in and with pharma, biotech and healthcare.

QuintilesIMS changes its name to IQVIA

QuintilesIMS changes its name to IQVIA

Firm will focus on human data science solutions. A year after its initial launch as QuintilesIMS, the pharma service provider has re-launched as IQVIA. ... Bousbib added: “We launched as QuintilesIMS, then we built something transformational and that

Latest news

  • Teva faces early rival to longer-acting Copaxone in US Teva faces early rival to longer-acting Copaxone in US

    formulation making $700m in that period, according to QuintilesIMS data.

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    Personalised medicine challenges. The QuintilesIMS meeting also discussed the scale of the health technology assessment challenge presented by personalised medicines, particularly in oncology. ... There will be a full report on QuintilesIMS' Question

  • INC Research to merge with InVentiv Health INC Research to merge with InVentiv Health

    Combined will be second-largest outsourcing provider after QuintilesIMS. Contract research organisation INC Research and commercial services firm InVentiv Health are to combine to create the second largest biopharmaceutical outsourcing provider.

  • La La Land? The myth of multichannel excellence La La Land? The myth of multichannel excellence

    As QuintilesIMS’ report into the core challenge of multichannel marketing - Channel Preference Versus Promotional Reality - points out, the traditional sales rep model that has disappeared in many other industries remains strong

  • QuintilesIMS launches European oncology data-gathering initiative QuintilesIMS launches European oncology data-gathering initiative

    Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer. QuintilesIMS has teamed up with four big pharma firms to gather insights into the real-world use of oncology therapies ... Currently, treatment-use information in Europe is based

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics